Logo of Renerve (ASX:RNV)Latest Renerve (ASX:RNV) News

Page 1
Page 1 of 5

ReNerve takes NervAlign into India as quarterly sales hit $584,000

ReNerve has converted Indian regulatory approval into its first commercial NervAlign Nerve Cuff procedure, with a Bangalore patient treated for an upper-extremity nerve repair. The milestone arrives after record quarterly sales of $584,000 and expands the company’s Asia-Pacific rollout.
Victor Sage
17 Nov 2026

ReNerve sales surge as quarterly revenue reaches record $584,000

ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.
Victor Sage
26 Oct 2026

ReNerve gains FDA clarity for NervAlign nerve guide submission

ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.
Victor Sage
14 Oct 2026

ReNerve reports 88% revenue growth as nerve repair pipeline moves toward commercialisation

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
5 Oct 2026

Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.
Logan Eniac
26 Sept 2026

ReNerve turns Asia-Pacific approvals into first Hong Kong and Malaysia surgeries

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.
Victor Sage
21 Sept 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

ReNerve Accelerates Global Nerve Repair Push with 80% Revenue Surge and FDA Progress

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.
Ada Torres
19 Aug 2026

Market Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Small explorers led the ASX week, with Lachlan Star, EcoGraf and Basin Energy recording the biggest gains on new drilling, offtake and exploration news.
Takeovers, capital raisings and strong company results also drew attention, although several large stocks fell despite reporting better earnings.
Logan Eniac
15 Aug 2026

Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.
Logan Eniac
15 Aug 2026

ReNerve Secures Indian Approval for NervAlign Nerve Cuff, Unlocking $700 Million Market

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.
Ada Torres
10 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026